English

AYTU BIOPHARMA, INC.

EDGAR

AYTU Annual report (10-K) · filed 2026-09-22

Annual consolidated revenue for 2026: about USD 57.57M, using the latest reported figures. The previous period, 2025, was about USD 66.38M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

16.1 million USD

2026 Q4 · USD

Exact inputs and evidence

Revenue: 57570000 USD Source
Revenue: 41464000 USD Source

Operating margin

-4.82%

2026 Q4 · %

Exact inputs and evidence

Operating Income: -8315000 USD Source
Operating Income: -7538000 USD Source
Revenue: 57570000 USD Source
Revenue: 41464000 USD Source

Operating cash flow

4.41 million USD

2026 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: 3281000 USD Source
Operating Cash Flow: -1125000 USD Source

Free cash flow

4.39 million USD

2026 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: 3281000 USD Source
Operating Cash Flow: -1125000 USD Source
Capital Expenditure: 29000 USD Source
Capital Expenditure: 17000 USD Source

Cash and cash equivalents: 26.3 million USD 2026-06-30 Source
Exact value

26308000 USD
Long-term debt including current maturities: 15 million Unit_Standard_USD_5a2GAEOOo0KevkIqUTVOoQ 2023-09-30 Source
Exact value

15000000 Unit_Standard_USD_5a2GAEOOo0KevkIqUTVOoQ
Shares outstanding: 10.7 million shares 2026-06-30 Source
Exact value

10728208 shares

Reported share-count change

19.51% · 1.75 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

8976913 shares · 2025-06-30· Source
10728208 shares · 2026-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-09-22.

Financial data available through: 2026-06-30.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2026-06-30
Operating income: 9 of 11 periods available· newest 2026-06-30
Net income: 9 of 11 periods available· newest 2026-06-30
Operating cash flow: 9 of 11 periods available· newest 2026-06-30
Capital expenditure: 8 of 11 periods available· newest 2026-06-30
Total assets: 9 of 11 periods available· newest 2026-06-30
Total liabilities: Multiple units; comparison withheld· newest 2023-06-30
Current assets: 9 of 11 periods available· newest 2026-06-30
Current liabilities: 9 of 11 periods available· newest 2026-06-30
Cash and cash equivalents: 9 of 11 periods available· newest 2026-06-30
Long-term debt including current maturities: 1 of 11 periods available· newest 2023-06-30
Shares outstanding: 9 of 11 periods available· newest 2026-06-30

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-13.3%

Prior period

USD 66.38 million

2024-07-01 – 2025-06-30
Current period

USD 57.57 million

2025-07-01 – 2026-06-30

Exact inputs and evidence

57570000 − 66382000 = -8812000 USD

66382000 USD · 2024-07-01 – 2025-06-30
Inspect prior input Prior source
57570000 USD · 2025-07-01 – 2026-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · AYTU BIOPHARMA, INC. · 2026-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Year-over-year change in Revenue: -8812000 USD Concept: fundies:Revenue Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 57570000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#902972 Filing: 000143774926030908 Input fundies:Revenue: 66382000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#903689 Filing: 000143774926030908
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 690,000

Prior period

−USD 13.56 million

2024-07-01 – 2025-06-30
Current period

−USD 14.25 million

2025-07-01 – 2026-06-30

Exact inputs and evidence

-14252000 − -13562000 = -690000 USD

-13562000 USD · 2024-07-01 – 2025-06-30
Inspect prior input Prior source
-14252000 USD · 2025-07-01 – 2026-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · AYTU BIOPHARMA, INC. · 2026-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Year-over-year change in Net income: -690000 USD Concept: fundies:NetIncome Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -14252000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1010143 Filing: 000143774926030908 Input fundies:NetIncome: -13562000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1010827 Filing: 000143774926030908
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 5.22 million

Prior period

−USD 1.94 million

2024-07-01 – 2025-06-30
Current period

USD 3.28 million

2025-07-01 – 2026-06-30

Exact inputs and evidence

3281000 − -1937000 = 5218000 USD

-1937000 USD · 2024-07-01 – 2025-06-30
Inspect prior input Prior source
3281000 USD · 2025-07-01 – 2026-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · AYTU BIOPHARMA, INC. · 2026-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Year-over-year change in Operating cash flow: 5218000 USD Concept: fundies:OperatingCashFlow Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 3281000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1040429 Filing: 000143774926030908 Input fundies:OperatingCashFlow: -1937000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1041237 Filing: 000143774926030908
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-87.3%

Prior period

USD 228,000

2024-07-01 – 2025-06-30
Current period

USD 29,000

2025-07-01 – 2026-06-30

Exact inputs and evidence

29000 − 228000 = -199000 USD

228000 USD · 2024-07-01 – 2025-06-30
Inspect prior input Prior source
29000 USD · 2025-07-01 – 2026-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · AYTU BIOPHARMA, INC. · 2026-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Year-over-year change in Capital expenditure: -199000 USD Concept: fundies:CapitalExpenditure Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 29000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1046070 Filing: 000143774926030908 Input fundies:CapitalExpenditure: 228000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1046735 Filing: 000143774926030908
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2026 2025-07-01 – 2026-06-30

Revenue USD 57.57 million 100% of revenue
Cost of revenue USD 20.75 million 36% of revenue
Operating expenses USD 45.13 million 78% of revenue
Operating income −USD 8.32 million −14% of revenue
Tax, interest and other Derived USD 5.94 million 10% of revenue
Net income −USD 14.25 million −25% of revenue

Cash

Operating cash flow USD 3.28 million 5.7% of revenue
Capital expenditure USD 29,000 0.1% of revenue
Free cash flow Derived USD 3.25 million 5.6% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 947% of revenue.
2017 Operating loss: operating costs were 725% of revenue.
2018 Operating loss: operating costs were 638% of revenue.
2019 Operating loss: operating costs were 330% of revenue.
2020 Operating loss: operating costs were 176% of revenue.
2023 Operating loss: operating costs were 110% of revenue.
2024 Operating loss: operating costs were 102% of revenue.
2025 Operating loss: operating costs were 112% of revenue.
2026 Operating loss: operating costs were 114% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2015-07-01 – 2016-06-30	2562445	24266842 Derived	-21704397	6475687 Derived	-28180084	-10910381 Derived	Source 2015-07-01 – 2016-06-30: 2562445 USD Inspect Revenue Open source 2015-07-01 – 2016-06-30: -21704397 USD Inspect Operating Income Open source 2015-07-01 – 2016-06-30: -28180084 USD Inspect Net Income Open source 2015-07-01 – 2016-06-30: -10657449 USD Inspect Operating Cash Flow Open source 2015-07-01 – 2016-06-30: 252932 USD Inspect Capital Expenditure Open source
2017 2016-07-01 – 2017-06-30	3221590	23346826 Derived	-20125236	2383068 Derived	-22508304	-13941260 Derived	Source 2016-07-01 – 2017-06-30: 3221590 USD Inspect Revenue Open source 2016-07-01 – 2017-06-30: -20125236 USD Inspect Operating Income Open source 2016-07-01 – 2017-06-30: -22508304 USD Inspect Net Income Open source 2016-07-01 – 2017-06-30: -13829652 USD Inspect Operating Cash Flow Open source 2016-07-01 – 2017-06-30: 111608 USD Inspect Capital Expenditure Open source
2018 2017-07-01 – 2018-06-30	3660120	23360354 Derived	-19700234	-9512371 Derived	-10187863	-16015029 Derived	Source 2017-07-01 – 2018-06-30: 3660120 USD Inspect Revenue Open source 2017-07-01 – 2018-06-30: -19700234 USD Inspect Operating Income Open source 2017-07-01 – 2018-06-30: -10187863 USD Inspect Net Income Open source 2017-07-01 – 2018-06-30: -15940322 USD Inspect Operating Cash Flow Open source 2017-07-01 – 2018-06-30: 74707 USD Inspect Capital Expenditure Open source
2019 2018-07-01 – 2019-06-30	7320357	24166994 Derived	-16846637	10285271 Derived	-27131908	-13891225 Derived	Source 2018-07-01 – 2019-06-30: 7320357 USD Inspect Revenue Open source 2018-07-01 – 2019-06-30: -16846637 USD Inspect Operating Income Open source 2018-07-01 – 2019-06-30: -27131908 USD Inspect Net Income Open source 2018-07-01 – 2019-06-30: -13831377 USD Inspect Operating Cash Flow Open source 2018-07-01 – 2019-06-30: 59848 USD Inspect Capital Expenditure Open source
2020 2019-07-01 – 2020-06-30	27632080	48762626 Derived	-21130546	-7509867 Derived	-13620679	-28373887 Derived	Source 2019-07-01 – 2020-06-30: 27632080 USD Inspect Revenue Open source 2019-07-01 – 2020-06-30: -21130546 USD Inspect Operating Income Open source 2019-07-01 – 2020-06-30: -13620679 USD Inspect Net Income Open source 2019-07-01 – 2020-06-30: -28373887 USD Inspect Operating Cash Flow Open source 2019-07-01 – 2020-06-30: 0 USD Inspect Capital Expenditure Open source
2023 2022-07-01 – 2023-06-30	73799000	81157000 Derived	-7358000	9693000 Derived	-17051000	Unavailable	Source 2022-07-01 – 2023-06-30: 73799000 USD Inspect Revenue Open source 2022-07-01 – 2023-06-30: -7358000 USD Inspect Operating Income Open source 2022-07-01 – 2023-06-30: -17051000 USD Inspect Net Income Open source 2022-07-01 – 2023-06-30: -5129000 USD Inspect Operating Cash Flow Open source
2024 2023-07-01 – 2024-06-30	65183000	66774000 Derived	-1591000	14253000 Derived	-15844000	-1717000 Derived	Source 2023-07-01 – 2024-06-30: 65183000 USD Inspect Revenue Open source 2023-07-01 – 2024-06-30: -1591000 USD Inspect Operating Income Open source 2023-07-01 – 2024-06-30: -15844000 USD Inspect Net Income Open source 2023-07-01 – 2024-06-30: -1388000 USD Inspect Operating Cash Flow Open source 2023-07-01 – 2024-06-30: 329000 USD Inspect Capital Expenditure Open source
2025 2024-07-01 – 2025-06-30	66382000	74209000 Derived	-7827000	5735000 Derived	-13562000	-2165000 Derived	Source 2024-07-01 – 2025-06-30: 66382000 USD Inspect Revenue Open source 2024-07-01 – 2025-06-30: -7827000 USD Inspect Operating Income Open source 2024-07-01 – 2025-06-30: -13562000 USD Inspect Net Income Open source 2024-07-01 – 2025-06-30: -1937000 USD Inspect Operating Cash Flow Open source 2024-07-01 – 2025-06-30: 228000 USD Inspect Capital Expenditure Open source
2026 2025-07-01 – 2026-06-30	57570000	65885000 Derived	-8315000	5937000 Derived	-14252000	3252000 Derived	Source 2025-07-01 – 2026-06-30: 57570000 USD Inspect Revenue Open source 2025-07-01 – 2026-06-30: -8315000 USD Inspect Operating Income Open source 2025-07-01 – 2026-06-30: -14252000 USD Inspect Net Income Open source 2025-07-01 – 2026-06-30: 3281000 USD Inspect Operating Cash Flow Open source 2025-07-01 – 2026-06-30: 29000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 57.6M 2026

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-06-30	Revenue	2562445	Revenue: 2562445 Open source
20172017-06-30	Revenue	3221590	Revenue: 3221590 Open source
20182018-06-30	Revenue	3660120	Revenue: 3660120 Open source
20192019-06-30	Revenue	7320357	Revenue: 7320357 Open source
20202020-06-30	Revenue	27632080	Revenue: 27632080 Open source
20232023-06-30	Revenue	73799000	Revenue: 73799000 Open source
20242024-06-30	Revenue	65183000	Revenue: 65183000 Open source
20252025-06-30	Revenue	66382000	Revenue: 66382000 Open source
20262026-06-30	Revenue	57570000	Revenue: 57570000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-13.3% 2026

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-06-30	Year over year	No prior comparable period	Revenue: 2562445 Open source
20172017-06-30	Year over year	25.7%	Revenue: 3221590 Open source Revenue: 2562445 Open source
20182018-06-30	Year over year	13.6%	Revenue: 3660120 Open source Revenue: 3221590 Open source
20192019-06-30	Year over year	100%	Revenue: 7320357 Open source Revenue: 3660120 Open source
20202020-06-30	Year over year	277.5%	Revenue: 27632080 Open source Revenue: 7320357 Open source
20232023-06-30	Year over year	No prior comparable period	Revenue: 73799000 Open source
20242024-06-30	Year over year	-11.7%	Revenue: 65183000 Open source Revenue: 73799000 Open source
20252025-06-30	Year over year	1.8%	Revenue: 66382000 Open source Revenue: 65183000 Open source
20262026-06-30	Year over year	-13.3%	Revenue: 57570000 Open source Revenue: 66382000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -14.4% 2026

Net margin -24.8% 2026

Free cash flow margin 5.6% 2026

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-06-30	Operating margin	-847%	Operating Income: -21704397 Open source Revenue: 2562445 Open source
20172017-06-30	Operating margin	-624.7%	Operating Income: -20125236 Open source Revenue: 3221590 Open source
20182018-06-30	Operating margin	-538.2%	Operating Income: -19700234 Open source Revenue: 3660120 Open source
20192019-06-30	Operating margin	-230.1%	Operating Income: -16846637 Open source Revenue: 7320357 Open source
20202020-06-30	Operating margin	-76.5%	Operating Income: -21130546 Open source Revenue: 27632080 Open source
20232023-06-30	Operating margin	-10%	Operating Income: -7358000 Open source Revenue: 73799000 Open source
20242024-06-30	Operating margin	-2.4%	Operating Income: -1591000 Open source Revenue: 65183000 Open source
20252025-06-30	Operating margin	-11.8%	Operating Income: -7827000 Open source Revenue: 66382000 Open source
20262026-06-30	Operating margin	-14.4%	Operating Income: -8315000 Open source Revenue: 57570000 Open source
20162016-06-30	Net margin	-1,099.7%	Net Income: -28180084 Open source Revenue: 2562445 Open source
20172017-06-30	Net margin	-698.7%	Net Income: -22508304 Open source Revenue: 3221590 Open source
20182018-06-30	Net margin	-278.3%	Net Income: -10187863 Open source Revenue: 3660120 Open source
20192019-06-30	Net margin	-370.6%	Net Income: -27131908 Open source Revenue: 7320357 Open source
20202020-06-30	Net margin	-49.3%	Net Income: -13620679 Open source Revenue: 27632080 Open source
20232023-06-30	Net margin	-23.1%	Net Income: -17051000 Open source Revenue: 73799000 Open source
20242024-06-30	Net margin	-24.3%	Net Income: -15844000 Open source Revenue: 65183000 Open source
20252025-06-30	Net margin	-20.4%	Net Income: -13562000 Open source Revenue: 66382000 Open source
20262026-06-30	Net margin	-24.8%	Net Income: -14252000 Open source Revenue: 57570000 Open source
20162016-06-30	Free cash flow margin	-425.8%	Revenue: 2562445 Open source Operating Cash Flow: -10657449 Open source Capital Expenditure: 252932 Open source
20172017-06-30	Free cash flow margin	-432.7%	Revenue: 3221590 Open source Operating Cash Flow: -13829652 Open source Capital Expenditure: 111608 Open source
20182018-06-30	Free cash flow margin	-437.6%	Revenue: 3660120 Open source Operating Cash Flow: -15940322 Open source Capital Expenditure: 74707 Open source
20192019-06-30	Free cash flow margin	-189.8%	Revenue: 7320357 Open source Operating Cash Flow: -13831377 Open source Capital Expenditure: 59848 Open source
20202020-06-30	Free cash flow margin	-102.7%	Revenue: 27632080 Open source Operating Cash Flow: -28373887 Open source Capital Expenditure: 0 Open source
20232023-06-30	Free cash flow margin	Not reported	Revenue: 73799000 Open source Operating Cash Flow: -5129000 Open source
20242024-06-30	Free cash flow margin	-2.6%	Revenue: 65183000 Open source Operating Cash Flow: -1388000 Open source Capital Expenditure: 329000 Open source
20252025-06-30	Free cash flow margin	-3.3%	Revenue: 66382000 Open source Operating Cash Flow: -1937000 Open source Capital Expenditure: 228000 Open source
20262026-06-30	Free cash flow margin	5.6%	Revenue: 57570000 Open source Operating Cash Flow: 3281000 Open source Capital Expenditure: 29000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 3.3M 2026

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-06-30	Operating cash flow	-10657449	Operating Cash Flow: -10657449 Open source
20172017-06-30	Operating cash flow	-13829652	Operating Cash Flow: -13829652 Open source
20182018-06-30	Operating cash flow	-15940322	Operating Cash Flow: -15940322 Open source
20192019-06-30	Operating cash flow	-13831377	Operating Cash Flow: -13831377 Open source
20202020-06-30	Operating cash flow	-28373887	Operating Cash Flow: -28373887 Open source
20232023-06-30	Operating cash flow	-5129000	Operating Cash Flow: -5129000 Open source
20242024-06-30	Operating cash flow	-1388000	Operating Cash Flow: -1388000 Open source
20252025-06-30	Operating cash flow	-1937000	Operating Cash Flow: -1937000 Open source
20262026-06-30	Operating cash flow	3281000	Operating Cash Flow: 3281000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 3.3M 2026

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-06-30	Free cash flow	-10910381	Operating Cash Flow: -10657449 Open source Capital Expenditure: 252932 Open source
20172017-06-30	Free cash flow	-13941260	Operating Cash Flow: -13829652 Open source Capital Expenditure: 111608 Open source
20182018-06-30	Free cash flow	-16015029	Operating Cash Flow: -15940322 Open source Capital Expenditure: 74707 Open source
20192019-06-30	Free cash flow	-13891225	Operating Cash Flow: -13831377 Open source Capital Expenditure: 59848 Open source
20202020-06-30	Free cash flow	-28373887	Operating Cash Flow: -28373887 Open source Capital Expenditure: 0 Open source
20232023-06-30	Free cash flow	Unavailable	Operating Cash Flow: -5129000 Open source
20242024-06-30	Free cash flow	-1717000	Operating Cash Flow: -1388000 Open source Capital Expenditure: 329000 Open source
20252025-06-30	Free cash flow	-2165000	Operating Cash Flow: -1937000 Open source Capital Expenditure: 228000 Open source
20262026-06-30	Free cash flow	3252000	Operating Cash Flow: 3281000 Open source Capital Expenditure: 29000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2016-06-30	Liabilities / assets	Not reported	Total Assets: 24343007 Open source
2017-06-30	Liabilities / assets	Not reported	Total Assets: 14998517 Open source
2018-06-30	Liabilities / assets	Not reported	Total Assets: 21060093 Open source
2019-06-30	Liabilities / assets	Not reported	Total Assets: 34721391 Open source
2020-06-30	Liabilities / assets	Not reported	Total Assets: 152836330 Open source
2023-06-30	Liabilities / assets	Not reported	Total Assets: 136463000 Open source
2024-06-30	Liabilities / assets	Not reported	Total Assets: 118095000 Open source
2025-06-30	Liabilities / assets	Not reported	Total Assets: 124177000 Open source
2026-06-30	Liabilities / assets	Not reported	Total Assets: 105007000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.13× 2026

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-06-30	Current assets / current liabilities	1×	Current Assets: 10120227 Open source Current Liabilities: 10104425 Open source
20172017-06-30	Current assets / current liabilities	0.84×	Current Assets: 3028562 Open source Current Liabilities: 3610468 Open source
20182018-06-30	Current assets / current liabilities	2.79×	Current Assets: 9470291 Open source Current Liabilities: 3394778 Open source
20192019-06-30	Current assets / current liabilities	2.87×	Current Assets: 15432864 Open source Current Liabilities: 5372576 Open source
20202020-06-30	Current assets / current liabilities	2.65×	Current Assets: 74965772 Open source Current Liabilities: 28306581 Open source
20232023-06-30	Current assets / current liabilities	1.03×	Current Assets: 71079000 Open source Current Liabilities: 69015000 Open source
20242024-06-30	Current assets / current liabilities	0.99×	Current Assets: 61891000 Open source Current Liabilities: 62228000 Open source
20252025-06-30	Current assets / current liabilities	1.26×	Current Assets: 79179000 Open source Current Liabilities: 63064000 Open source
20262026-06-30	Current assets / current liabilities	1.13×	Current Assets: 61761000 Open source Current Liabilities: 54659000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2015-07-01 – 2016-06-30	−USD 28.18 million Exact value Exact value: -28180084 USD 2015-07-01 – 2016-06-30: -28180084 USD Inspect Net Income Open source Share or cite Citation for Net Income · AYTU BIOPHARMA, INC. · 2016-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Net Income: -28180084 USD Concept: fundies:NetIncome Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ANetIncome&period=2016-06-30&surface=latest&period_type=duration&start=2015-07-01&unit=USD&dimensions= Input fundies:NetIncome: -28180084 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000121390018001614/aytu-20171231.xml#282648 Filing: 000121390018001614 The citation records this snapshot. The page link may show a newer release later.	−USD 10.66 million Exact value Exact value: -10657449 USD 2015-07-01 – 2016-06-30: -10657449 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AYTU BIOPHARMA, INC. · 2016-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Operating Cash Flow: -10657449 USD Concept: fundies:OperatingCashFlow Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3AOperatingCashFlow&period=2016-06-30&surface=latest&period_type=duration&start=2015-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10657449 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000121390018001614/aytu-20171231.xml#351097 Filing: 000121390018001614 The citation records this snapshot. The page link may show a newer release later.	USD 252,932 Exact value Exact value: 252932 USD 2015-07-01 – 2016-06-30: 252932 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AYTU BIOPHARMA, INC. · 2016-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Capital Expenditure: 252932 USD Concept: fundies:CapitalExpenditure Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ACapitalExpenditure&period=2016-06-30&surface=latest&period_type=duration&start=2015-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 252932 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000121390018001614/aytu-20171231.xml#352103 Filing: 000121390018001614 The citation records this snapshot. The page link may show a newer release later.	−USD 10.91 million Calculation and evidence -10657449 − 252932 USD Exact free cash flow: -10910381 USD 2015-07-01 – 2016-06-30: -10657449 USD · Inspect Operating Cash Flow · Source 2015-07-01 – 2016-06-30: 252932 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AYTU BIOPHARMA, INC. · 2016-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Free cash flow: -10910381 USD Concept: free-cash-flow Period: 2015-07-01 to 2016-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10657449 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000121390018001614/aytu-20171231.xml#351097 Filing: 000121390018001614 Input fundies:CapitalExpenditure: 252932 USD (2015-07-01 to 2016-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000121390018001614/aytu-20171231.xml#352103 Filing: 000121390018001614 The citation records this snapshot. The page link may show a newer release later.
2017 2016-07-01 – 2017-06-30	−USD 22.51 million Exact value Exact value: -22508304 USD 2016-07-01 – 2017-06-30: -22508304 USD Inspect Net Income Open source Share or cite Citation for Net Income · AYTU BIOPHARMA, INC. · 2017-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Net Income: -22508304 USD Concept: fundies:NetIncome Period: 2016-07-01 to 2017-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ANetIncome&period=2017-06-30&surface=latest&period_type=duration&start=2016-07-01&unit=USD&dimensions= Input fundies:NetIncome: -22508304 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000121390018012209/aytu-20180630.xml#162364 Filing: 000121390018012209 The citation records this snapshot. The page link may show a newer release later.	−USD 13.83 million Exact value Exact value: -13829652 USD 2016-07-01 – 2017-06-30: -13829652 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AYTU BIOPHARMA, INC. · 2017-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Operating Cash Flow: -13829652 USD Concept: fundies:OperatingCashFlow Period: 2016-07-01 to 2017-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3AOperatingCashFlow&period=2017-06-30&surface=latest&period_type=duration&start=2016-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13829652 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000121390018012209/aytu-20180630.xml#551627 Filing: 000121390018012209 The citation records this snapshot. The page link may show a newer release later.	USD 111,608 Exact value Exact value: 111608 USD 2016-07-01 – 2017-06-30: 111608 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AYTU BIOPHARMA, INC. · 2017-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Capital Expenditure: 111608 USD Concept: fundies:CapitalExpenditure Period: 2016-07-01 to 2017-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ACapitalExpenditure&period=2017-06-30&surface=latest&period_type=duration&start=2016-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 111608 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000121390018012209/aytu-20180630.xml#356144 Filing: 000121390018012209 The citation records this snapshot. The page link may show a newer release later.	−USD 13.94 million Calculation and evidence -13829652 − 111608 USD Exact free cash flow: -13941260 USD 2016-07-01 – 2017-06-30: -13829652 USD · Inspect Operating Cash Flow · Source 2016-07-01 – 2017-06-30: 111608 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AYTU BIOPHARMA, INC. · 2017-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Free cash flow: -13941260 USD Concept: free-cash-flow Period: 2016-07-01 to 2017-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13829652 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000121390018012209/aytu-20180630.xml#551627 Filing: 000121390018012209 Input fundies:CapitalExpenditure: 111608 USD (2016-07-01 to 2017-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000121390018012209/aytu-20180630.xml#356144 Filing: 000121390018012209 The citation records this snapshot. The page link may show a newer release later.
2018 2017-07-01 – 2018-06-30	−USD 10.19 million Exact value Exact value: -10187863 USD 2017-07-01 – 2018-06-30: -10187863 USD Inspect Net Income Open source Share or cite Citation for Net Income · AYTU BIOPHARMA, INC. · 2018-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Net Income: -10187863 USD Concept: fundies:NetIncome Period: 2017-07-01 to 2018-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ANetIncome&period=2018-06-30&surface=latest&period_type=duration&start=2017-07-01&unit=USD&dimensions= Input fundies:NetIncome: -10187863 USD (2017-07-01 to 2018-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000165495419011147/aytu-20190630.xml#98630 Filing: 000165495419011147 The citation records this snapshot. The page link may show a newer release later.	−USD 15.94 million Exact value Exact value: -15940322 USD 2017-07-01 – 2018-06-30: -15940322 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AYTU BIOPHARMA, INC. · 2018-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Operating Cash Flow: -15940322 USD Concept: fundies:OperatingCashFlow Period: 2017-07-01 to 2018-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3AOperatingCashFlow&period=2018-06-30&surface=latest&period_type=duration&start=2017-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15940322 USD (2017-07-01 to 2018-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000165495419011147/aytu-20190630.xml#102839 Filing: 000165495419011147 The citation records this snapshot. The page link may show a newer release later.	USD 74,707 Exact value Exact value: 74707 USD 2017-07-01 – 2018-06-30: 74707 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AYTU BIOPHARMA, INC. · 2018-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Capital Expenditure: 74707 USD Concept: fundies:CapitalExpenditure Period: 2017-07-01 to 2018-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ACapitalExpenditure&period=2018-06-30&surface=latest&period_type=duration&start=2017-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 74707 USD (2017-07-01 to 2018-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000165495419011147/aytu-20190630.xml#107104 Filing: 000165495419011147 The citation records this snapshot. The page link may show a newer release later.	−USD 16.02 million Calculation and evidence -15940322 − 74707 USD Exact free cash flow: -16015029 USD 2017-07-01 – 2018-06-30: -15940322 USD · Inspect Operating Cash Flow · Source 2017-07-01 – 2018-06-30: 74707 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AYTU BIOPHARMA, INC. · 2018-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Free cash flow: -16015029 USD Concept: free-cash-flow Period: 2017-07-01 to 2018-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15940322 USD (2017-07-01 to 2018-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000165495419011147/aytu-20190630.xml#102839 Filing: 000165495419011147 Input fundies:CapitalExpenditure: 74707 USD (2017-07-01 to 2018-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000165495419011147/aytu-20190630.xml#107104 Filing: 000165495419011147 The citation records this snapshot. The page link may show a newer release later.
2019 2018-07-01 – 2019-06-30	−USD 27.13 million Exact value Exact value: -27131908 USD 2018-07-01 – 2019-06-30: -27131908 USD Inspect Net Income Open source Share or cite Citation for Net Income · AYTU BIOPHARMA, INC. · 2019-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Net Income: -27131908 USD Concept: fundies:NetIncome Period: 2018-07-01 to 2019-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ANetIncome&period=2019-06-30&surface=latest&period_type=duration&start=2018-07-01&unit=USD&dimensions= Input fundies:NetIncome: -27131908 USD (2018-07-01 to 2019-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000165495420010891/aytu-20200630.xml#163280 Filing: 000165495420010891 The citation records this snapshot. The page link may show a newer release later.	−USD 13.83 million Exact value Exact value: -13831377 USD 2018-07-01 – 2019-06-30: -13831377 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AYTU BIOPHARMA, INC. · 2019-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Operating Cash Flow: -13831377 USD Concept: fundies:OperatingCashFlow Period: 2018-07-01 to 2019-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3AOperatingCashFlow&period=2019-06-30&surface=latest&period_type=duration&start=2018-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13831377 USD (2018-07-01 to 2019-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000165495420010891/aytu-20200630.xml#187753 Filing: 000165495420010891 The citation records this snapshot. The page link may show a newer release later.	USD 59,848 Exact value Exact value: 59848 USD 2018-07-01 – 2019-06-30: 59848 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AYTU BIOPHARMA, INC. · 2019-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Capital Expenditure: 59848 USD Concept: fundies:CapitalExpenditure Period: 2018-07-01 to 2019-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ACapitalExpenditure&period=2019-06-30&surface=latest&period_type=duration&start=2018-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 59848 USD (2018-07-01 to 2019-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000165495420010891/aytu-20200630.xml#196243 Filing: 000165495420010891 The citation records this snapshot. The page link may show a newer release later.	−USD 13.89 million Calculation and evidence -13831377 − 59848 USD Exact free cash flow: -13891225 USD 2018-07-01 – 2019-06-30: -13831377 USD · Inspect Operating Cash Flow · Source 2018-07-01 – 2019-06-30: 59848 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AYTU BIOPHARMA, INC. · 2019-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Free cash flow: -13891225 USD Concept: free-cash-flow Period: 2018-07-01 to 2019-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13831377 USD (2018-07-01 to 2019-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000165495420010891/aytu-20200630.xml#187753 Filing: 000165495420010891 Input fundies:CapitalExpenditure: 59848 USD (2018-07-01 to 2019-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000165495420010891/aytu-20200630.xml#196243 Filing: 000165495420010891 The citation records this snapshot. The page link may show a newer release later.
2020 2019-07-01 – 2020-06-30	−USD 13.62 million Exact value Exact value: -13620679 USD 2019-07-01 – 2020-06-30: -13620679 USD Inspect Net Income Open source Share or cite Citation for Net Income · AYTU BIOPHARMA, INC. · 2020-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Net Income: -13620679 USD Concept: fundies:NetIncome Period: 2019-07-01 to 2020-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ANetIncome&period=2020-06-30&surface=latest&period_type=duration&start=2019-07-01&unit=USD&dimensions= Input fundies:NetIncome: -13620679 USD (2019-07-01 to 2020-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000165495420010891/aytu-20200630.xml#163152 Filing: 000165495420010891 The citation records this snapshot. The page link may show a newer release later.	−USD 28.37 million Exact value Exact value: -28373887 USD 2019-07-01 – 2020-06-30: -28373887 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AYTU BIOPHARMA, INC. · 2020-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Operating Cash Flow: -28373887 USD Concept: fundies:OperatingCashFlow Period: 2019-07-01 to 2020-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3AOperatingCashFlow&period=2020-06-30&surface=latest&period_type=duration&start=2019-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28373887 USD (2019-07-01 to 2020-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000165495420010891/aytu-20200630.xml#187567 Filing: 000165495420010891 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2019-07-01 – 2020-06-30: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AYTU BIOPHARMA, INC. · 2020-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2019-07-01 to 2020-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ACapitalExpenditure&period=2020-06-30&surface=latest&period_type=duration&start=2019-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2019-07-01 to 2020-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000165495420010891/aytu-20200630.xml#196065 Filing: 000165495420010891 The citation records this snapshot. The page link may show a newer release later.	−USD 28.37 million Calculation and evidence -28373887 − 0 USD Exact free cash flow: -28373887 USD 2019-07-01 – 2020-06-30: -28373887 USD · Inspect Operating Cash Flow · Source 2019-07-01 – 2020-06-30: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AYTU BIOPHARMA, INC. · 2020-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Free cash flow: -28373887 USD Concept: free-cash-flow Period: 2019-07-01 to 2020-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28373887 USD (2019-07-01 to 2020-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000165495420010891/aytu-20200630.xml#187567 Filing: 000165495420010891 Input fundies:CapitalExpenditure: 0 USD (2019-07-01 to 2020-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000165495420010891/aytu-20200630.xml#196065 Filing: 000165495420010891 The citation records this snapshot. The page link may show a newer release later.
2023 2022-07-01 – 2023-06-30	−USD 17.05 million Exact value Exact value: -17051000 USD 2022-07-01 – 2023-06-30: -17051000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AYTU BIOPHARMA, INC. · 2023-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Net Income: -17051000 USD Concept: fundies:NetIncome Period: 2022-07-01 to 2023-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ANetIncome&period=2023-06-30&surface=latest&period_type=duration&start=2022-07-01&unit=USD&dimensions= Input fundies:NetIncome: -17051000 USD (2022-07-01 to 2023-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774925019189/aytu20250530_s1.htm#967536 Filing: 000143774925019189 The citation records this snapshot. The page link may show a newer release later.	−USD 5.13 million Exact value Exact value: -5129000 USD 2022-07-01 – 2023-06-30: -5129000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AYTU BIOPHARMA, INC. · 2023-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Operating Cash Flow: -5129000 USD Concept: fundies:OperatingCashFlow Period: 2022-07-01 to 2023-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3AOperatingCashFlow&period=2023-06-30&surface=latest&period_type=duration&start=2022-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5129000 USD (2022-07-01 to 2023-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774925019189/aytu20250530_s1.htm#1002948 Filing: 000143774925019189 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2023-07-01 – 2024-06-30	−USD 15.84 million Exact value Exact value: -15844000 USD 2023-07-01 – 2024-06-30: -15844000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AYTU BIOPHARMA, INC. · 2024-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Net Income: -15844000 USD Concept: fundies:NetIncome Period: 2023-07-01 to 2024-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ANetIncome&period=2024-06-30&surface=latest&period_type=duration&start=2023-07-01&unit=USD&dimensions= Input fundies:NetIncome: -15844000 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774925029723/aytu20250630c_10k.htm#1038370 Filing: 000143774925029723 The citation records this snapshot. The page link may show a newer release later.	−USD 1.39 million Exact value Exact value: -1388000 USD 2023-07-01 – 2024-06-30: -1388000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AYTU BIOPHARMA, INC. · 2024-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Operating Cash Flow: -1388000 USD Concept: fundies:OperatingCashFlow Period: 2023-07-01 to 2024-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3AOperatingCashFlow&period=2024-06-30&surface=latest&period_type=duration&start=2023-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1388000 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774925029723/aytu20250630c_10k.htm#1070533 Filing: 000143774925029723 The citation records this snapshot. The page link may show a newer release later.	USD 329,000 Exact value Exact value: 329000 USD 2023-07-01 – 2024-06-30: 329000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AYTU BIOPHARMA, INC. · 2024-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Capital Expenditure: 329000 USD Concept: fundies:CapitalExpenditure Period: 2023-07-01 to 2024-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ACapitalExpenditure&period=2024-06-30&surface=latest&period_type=duration&start=2023-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 329000 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774925029723/aytu20250630c_10k.htm#1076032 Filing: 000143774925029723 The citation records this snapshot. The page link may show a newer release later.	−USD 1.72 million Calculation and evidence -1388000 − 329000 USD Exact free cash flow: -1717000 USD 2023-07-01 – 2024-06-30: -1388000 USD · Inspect Operating Cash Flow · Source 2023-07-01 – 2024-06-30: 329000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AYTU BIOPHARMA, INC. · 2024-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Free cash flow: -1717000 USD Concept: free-cash-flow Period: 2023-07-01 to 2024-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1388000 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774925029723/aytu20250630c_10k.htm#1070533 Filing: 000143774925029723 Input fundies:CapitalExpenditure: 329000 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774925029723/aytu20250630c_10k.htm#1076032 Filing: 000143774925029723 The citation records this snapshot. The page link may show a newer release later.
2025 2024-07-01 – 2025-06-30	−USD 13.56 million Exact value Exact value: -13562000 USD 2024-07-01 – 2025-06-30: -13562000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AYTU BIOPHARMA, INC. · 2025-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Net Income: -13562000 USD Concept: fundies:NetIncome Period: 2024-07-01 to 2025-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ANetIncome&period=2025-06-30&surface=latest&period_type=duration&start=2024-07-01&unit=USD&dimensions= Input fundies:NetIncome: -13562000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1010827 Filing: 000143774926030908 The citation records this snapshot. The page link may show a newer release later.	−USD 1.94 million Exact value Exact value: -1937000 USD 2024-07-01 – 2025-06-30: -1937000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AYTU BIOPHARMA, INC. · 2025-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Operating Cash Flow: -1937000 USD Concept: fundies:OperatingCashFlow Period: 2024-07-01 to 2025-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3AOperatingCashFlow&period=2025-06-30&surface=latest&period_type=duration&start=2024-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1937000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1041237 Filing: 000143774926030908 The citation records this snapshot. The page link may show a newer release later.	USD 228,000 Exact value Exact value: 228000 USD 2024-07-01 – 2025-06-30: 228000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AYTU BIOPHARMA, INC. · 2025-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Capital Expenditure: 228000 USD Concept: fundies:CapitalExpenditure Period: 2024-07-01 to 2025-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ACapitalExpenditure&period=2025-06-30&surface=latest&period_type=duration&start=2024-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 228000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1046735 Filing: 000143774926030908 The citation records this snapshot. The page link may show a newer release later.	−USD 2.17 million Calculation and evidence -1937000 − 228000 USD Exact free cash flow: -2165000 USD 2024-07-01 – 2025-06-30: -1937000 USD · Inspect Operating Cash Flow · Source 2024-07-01 – 2025-06-30: 228000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AYTU BIOPHARMA, INC. · 2025-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Free cash flow: -2165000 USD Concept: free-cash-flow Period: 2024-07-01 to 2025-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1937000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1041237 Filing: 000143774926030908 Input fundies:CapitalExpenditure: 228000 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1046735 Filing: 000143774926030908 The citation records this snapshot. The page link may show a newer release later.
2026 2025-07-01 – 2026-06-30	−USD 14.25 million Exact value Exact value: -14252000 USD 2025-07-01 – 2026-06-30: -14252000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AYTU BIOPHARMA, INC. · 2026-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Net Income: -14252000 USD Concept: fundies:NetIncome Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ANetIncome&period=2026-06-30&surface=latest&period_type=duration&start=2025-07-01&unit=USD&dimensions= Input fundies:NetIncome: -14252000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1010143 Filing: 000143774926030908 The citation records this snapshot. The page link may show a newer release later.	USD 3.28 million Exact value Exact value: 3281000 USD 2025-07-01 – 2026-06-30: 3281000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AYTU BIOPHARMA, INC. · 2026-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Operating Cash Flow: 3281000 USD Concept: fundies:OperatingCashFlow Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3AOperatingCashFlow&period=2026-06-30&surface=latest&period_type=duration&start=2025-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 3281000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1040429 Filing: 000143774926030908 The citation records this snapshot. The page link may show a newer release later.	USD 29,000 Exact value Exact value: 29000 USD 2025-07-01 – 2026-06-30: 29000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AYTU BIOPHARMA, INC. · 2026-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Capital Expenditure: 29000 USD Concept: fundies:CapitalExpenditure Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818/explain?concept=fundies%3ACapitalExpenditure&period=2026-06-30&surface=latest&period_type=duration&start=2025-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 29000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1046070 Filing: 000143774926030908 The citation records this snapshot. The page link may show a newer release later.	USD 3.25 million Calculation and evidence 3281000 − 29000 USD Exact free cash flow: 3252000 USD 2025-07-01 – 2026-06-30: 3281000 USD · Inspect Operating Cash Flow · Source 2025-07-01 – 2026-06-30: 29000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AYTU BIOPHARMA, INC. · 2026-06-30 AYTU BIOPHARMA, INC. (edgar:1385818) Free cash flow: 3252000 USD Concept: free-cash-flow Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T09:16:12Z Snapshot: a900f235bbb54ac260ebf9d6ea0eace5566b9a2d3c623fd832677d62d4039583 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1385818?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 3281000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1040429 Filing: 000143774926030908 Input fundies:CapitalExpenditure: 29000 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/aytu20260630_10k.htm#1046070 Filing: 000143774926030908 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

189 filings · 6,263 latest values · 6,263 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001385818, 1385818, AYTU, RSWN, aytu, edgar:1385818

Also known as AYTU BIOPHARMA, INC, AYTU BIOPHARMA, INC., AYTU BIOPHARMA, INC., AYTU BIOSCIENCE, INC, AYTU BIOSCIENCE, INC., ROSEWIND CORP, Rosewind CORP

AYTU BIOPHARMA, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2026 2025-07-01 – 2026-06-30

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation